Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.
Investor's Business Daily on MSN1mon
Exact Sciences Stock Rises After FDA Signs Off On New CologuardExact Sciences rose Friday after the Food and Drug Administration approved its next-generation colon cancer detection test, ...
2 “Cologuard Plus sets a new performance standard in non-invasive colorectal cancer screening for patients,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “Cologuard Plus detects ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Recommended Reading Exact Sciences says data support ...
Exact Sciences Corp.’s Cologuard Plus received U.S. FDA pre-market approval as a non-invasive colorectal cancer home screening test. The next-generation, stool-based assay, developed in conjunction ...
Puneet Souda’s rating is based on the expectation of broader adoption and higher volumes for Exact Sciences’s Cologuard Plus (CG+), which is anticipated to have higher specificity compared to ...
Mark Massaro has given his Buy rating due to a combination of factors including the recent FDA approval and anticipated superior performance of Exact Sciences’ Cologuard Plus test. The analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback